Fluvoxamine for the treatment of COVID-19
- PMID: 35180412
- PMCID: PMC8846600
- DOI: 10.1016/S2214-109X(22)00006-7
Fluvoxamine for the treatment of COVID-19
Conflict of interest statement
MGD, EBD, FB, CRR are employed by Certara. Certara scientific support into the TOGETHER study was funded by the Bill and Melinda Gates Foundation. AMR is a co-applicant on a patent application filed by Washington University for the public use of generic selective serotonin reuptake inhibitors for COVID-19.
Comment in
-
Fluvoxamine for the treatment of COVID-19 - Author's reply.Lancet Glob Health. 2022 Mar;10(3):e333. doi: 10.1016/S2214-109X(21)00588-X. Lancet Glob Health. 2022. PMID: 35180413 Free PMC article. No abstract available.
Comment on
-
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial.Lancet Glob Health. 2022 Jan;10(1):e42-e51. doi: 10.1016/S2214-109X(21)00448-4. Epub 2021 Oct 28. Lancet Glob Health. 2022. PMID: 34717820 Free PMC article. Clinical Trial.
References
-
- Panchaud A, Garcia-Bournissen F, Csajka C, et al. Prediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine exposure. Clin Pharmacol Ther. 2011;89:830–836. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical